Résultats de recherche

Retour
1 - 10 de 65 Résultats de recherche

 - 

 - 

Ipsen réaffirme son engagement dans les maladies rares avec la publication de huit abstracts acceptés lors de l’ENDO 2020 et publiés dans le Journal of the Endocrine Society

Les données publiées évaluent la progression naturelle de la fibrodysplasieossifiante progressive (FOP) ou de l’acromégalieLa Natural History Study (NHS) est la première étude longitudinale définiepar protocole destinée à évaluer la progressi...


 - 

 - 

Ipsen provides update on palovarotene clinical programs

...


 - 

 - 

Ipsen reports solid sales growth in first quarter 2020 with limited COVID-19 impact

Paris (France), 22 April 2020 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical group, today announced its sales for the first quarter of 2020....


 - 

 - 

Ipsen delivers strong H1 2021 results and upgrades full-year guidance

...


 - 

 - 

Ipsen presents its 2019 results, provides 2020 guidance and updates 2022 financial outlook

Aymeric Le Chatelier, Chief Executive Officer and Chief Financial Officer of Ipsen, stated: “2019 was another excellent year of operating performance for Ipsen with continued double-digit top-line growth and core operating margin expansion. Despite the ...


 - 

 - 

Ipsen presents its half year 2020 results and reinstates guidance for full year 2020

David Loew, Chief Executive Officer of Ipsen, stated: “I’m honored since July 1st to lead Ipsen, an exciting global biopharma business with solid business fundamentals, a strong purpose to serve patients and attractive growth opportunities. I am enco...



 - 

 - 

Ipsen and Blueprint Medicines announce exclusive global license agreement to develop and commercialize BLU-782 for the treatment of fibrodysplasia ossificans progressiva (FOP)

— Expands Ipsen’s Rare Diseases portfolio to include BLU-782,a highly selective investigational ALK2 inhibitor for the treatment of FOP —— Accelerates global development of BLU-782 through Ipsen’s clinical expertisein rare diseases and global i...


 - 

 - 

Ipsen Initiates Partial Clinical Hold for Palovarotene IND120181 and IND135403 Studies

PARIS, France, 6 December 2019 — Ipsen (Euronext: IPN; ADR: IPSEY) today announced, following discussions with the U.S. Food and Drug Administration (FDA), that a partial clinical hold effective immediately, for the pediatric population under the age o...


1 … 4 5 6 7